modality directory

vaccine clinical trial intelligence

Trials are included when the normalized modality field matches this therapeutic modality. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

modality

Association rule

normalized field

NCT01096134

Source recordAI-normalized

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines by integrating the HPV vaccine for girls ages 9-13 into already successful screening and treatment programs for mothers.

AI analysis

Indication: Cervical Cancer

Modality: vaccine

Target: HPV Vaccine (Gardasil)

Sponsor: Jhpiego

Source URL: ClinicalTrials.gov

Source updated: Oct 12, 2015

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: vaccine

View original source fields

Condition raw: Cervical Cancer

Condition normalized: Cervical Cancer

Modality raw: vaccine

Modality normalized: vaccine

Target raw: HPV Vaccine (Gardasil)

Target normalized: HPV Vaccine (Gardasil)

Open report

NCT02612909

Source recordAI-normalized

A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC

The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses tested would be immunogenic in 60% or more of the subjects tested.

AI analysis

Indication: Avian Influenza

Modality: vaccine

Target: IVACFLU-A/H5N1 vaccine, Placebo

Sponsor: Institute of Vaccines and Medical Biologicals, Vietnam

Source URL: ClinicalTrials.gov

Source updated: May 21, 2019

Ingested: Jun 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: vaccine

View original source fields

Condition raw: Avian Influenza

Condition normalized: Avian Influenza

Modality raw: vaccine

Modality normalized: vaccine

Target raw: IVACFLU-A/H5N1 vaccine, Placebo

Target normalized: IVACFLU-A/H5N1 vaccine, Placebo

Open report

NCT01010893

Source recordAI-normalized

Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons

The clinical trial assessed the tolerability and immunogenicity of the FLUVAL P monovalent influenza vaccine in adults and elderly individuals. Conducted by Fluart Innovative Vaccine Ltd, the study aimed to verify the vaccine's efficacy and safety profile, particularly in the context of pandemic influenza prevention.

AI analysis

Indication: Influenza

Modality: vaccine

Target: Influenza

Sponsor: Fluart Innovative Vaccine Ltd, Hungary

Source URL: ClinicalTrials.gov

Source updated: May 21, 2012

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: vaccine

View original source fields

Condition raw: Influenza

Condition normalized: Influenza

Modality raw: Influenza

Modality normalized: vaccine

Target raw: Influenza

Target normalized: Influenza

Open report